Lupin announced the launch of Mirabegron Extended-Release Tablets, 50 mg, in the United States, after having received an approval from the United States Food and Drug Administration (U.S. FDA).
Mirabegron Extended-Release Tablets, 50 mg is a generic equivalent of Myrbetriq' Extended-Release Tablets, 50 mg of Astellas Pharma Global Development, Inc.
Mirabegron Extended-Release Tablets, 50 mg had estimated annual sales of USD 1,600 million in the U.S. (IQVIA MAT July 2024).
Low Price Shares
0 mins read . Dec 18, 2024
Nifty 50 Top 10 Stocks
0 mins read . Dec 18, 2024
Best Stocks in 2025
0 mins read . Dec 18, 2024
Explore our products
₹0 Brokerage *
Open Demat Account